# Filing Detail

Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001493152-25-018798
Filing Date
2025-10-21
Accepted
2025-10-21 16:49:28
Documents
10
Period of Report
2025-10-21

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | PRE 14A | formpre14a.htm | PRE 14A | 425147
2 | EX-1 | ex1.htm | EX-1 | 1522
3 | EX-2 | ex2.htm | EX-2 | 12751
4 | EX-3 | ex3.htm | EX-3 | 13043
5 | EX-4 | ex4.htm | EX-4 | 12991
6 | EX-5 | ex5.htm | EX-5 | 12857
7 | EX-7 | ex7.htm | EX-7 | 12047
8 | GRAPHIC | formpre14a_001.jpg | GRAPHIC | 4043
9 | GRAPHIC | ex1_001.jpg | GRAPHIC | 361806
10 | GRAPHIC | ex1_002.jpg | GRAPHIC | 224500
| Complete submission text file | 0001493152-25-018798.txt |  | 1304920

Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

EIN.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 000-21617 | Film No.: 251407676
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)